Liddle syndrome is a form of inherited hypertension or high blood pressure. People suffering from this disorder typically experience signs of hypertension early in life which appears to be fairly unusual. If left untreated, chronic hypertension from Liddle syndrome increases the risk of stroke, left ventricular hypertrophy, heart failure, and premature cardiovascular disease.
Liddle syndrome is a genetic cause of low-renin, low-aldosterone hypertension and is sometimes described as a form of pseudohyperaldosteronism. It is a rare genetic condition caused by constitutive activation of epithelial sodium channels in the kidney, leading to sodium retention and hypertension despite normal kidney structure. As a result, the affected person eventually suffers from hypertension.
Currently, medical researchers have not found a permanent cure for this syndrome. However, most individuals can manage the symptoms and progress of the disorder through ongoing medical care.
Liddle syndrome is caused by pathogenic variants in genes encoding ENaC subunits, most commonly SCNN1B and SCNN1G, and less commonly SCNN1A.
Beyond high blood pressure, there are certain clinical hallmarks of patients who might be suffering from Liddle syndrome. These include:
Although many of these symptoms overlap with those of Gordon's syndrome, clinical experts often highlight the notable absence of edema as a key distinguishing feature of Liddle syndrome. In some cases, the affected children may be asymptomatic until hypertension complications emerge.
The diagnosis of Liddle syndrome is approached in a clear, four-step process. First up, a designated team screens for resistant hypertension, which is when blood pressure readings exceed 140/90 mmHg even while taking three different antihypertensive medications.
Next, the doctors look at a biochemical triad for more conclusive evidence. This normally includes serum potassium levels dropping below 3.5 mmol/L, and plasma renin activity at 0.6 ng/mL/hr or lower.
In the third step, your healthcare provider will conduct a pharmacological test. Here, if the blood pressure normalizes with amiloride (5-20 mg/day) and there is no response to spironolactone, it speaks for a positive outcome of the diagnosis.
Genetic testing using sequencing of SCNN1A, SCNN1B, and SCNN1G can identify pathogenic variants in many affected individuals, though detection rates vary.
Finally, doctors need to rule out other possible diagnoses, such as apparent mineralocorticoid excess syndrome, congenital adrenal hyperplasia, and primary hyperaldosteronism.
Despite the numerous diagnostic challenges of Liddle syndrome, advancements in genetic testing and targeted treatments offer new rays of hope.
Though it goes without saying, a timely assessment is crucial for people with resistant hypertension.
Disclaimer: This article is intended for general informational and educational purposes only. Liddle syndrome is a rare genetic condition, and its diagnosis and management require individualized clinical evaluation, laboratory testing, and, in some cases, genetic analysis performed by trained medical specialists. If you have concerns about high blood pressure, electrolyte imbalances, or a suspected genetic condition, seek advice from a licensed physician or a qualified healthcare provider.
Also Read:
→ What is Hyperkalemic Periodic Paralysis Syndrome
→ What is the Coverage for Ehlers-Danlos Syndrome
→ How is Mowat-Wilson Syndrome Diagnosed
→ What is Cushing’s Syndrome Cortisol